Home Companies Catalysts Deep Dives
Breztri budesonide/glycopyrronium/formoterol APPROVED
Drug Profile
ModalityInhaler
RouteINHALATION
Therapy AreaR&I
Launch2020-07-24
US LOE2030-01-01
Peak Sales Est$2000M
Formulations[{"id":"breztri-inhaler","doses":"160/4.8/9.6 mcg","route":"Inhaled","setting":"PATIENT_SELF","frequ
Companies
AZN (ORIGINATOR)100%
Mechanism: ICS/LAMA/LABA combination
Expert: Fixed-dose combination of ICS (budesonide), LAMA (glycopyrronium), and LABA (formoterol) in pressurized metered-dose inhaler for COPD maintenance.
Everyday: Three medicines in one inhaler: anti-inflammatory steroid, long-acting bronchodilator, and another bronchodilator that works differently.
Targets: []
Revenue History
PeriodRevenue ($M)
2023$1,218M
2024$1,652M
Q1 2025$480M
Q2 2025$520M
Programs (1)
IndicationStageKey StudyRegional Status
COPDAPPROVEDETHOS[{"stage":"APPROVED","region":"US","approval_date":"2020-07-24"},{"stage":"APPRO
Notes
Triple therapy for COPD.
Data from Supabase · Updated 2026-03-24